Across TCGA pan-cancer cohorts, C16orf74 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C16orf74 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher C16orf74 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C16orf74 expression acts as an unfavorable survival marker.
HNSC and CCRCC are the cancer types where C16orf74 mass-spec protein most reproducibly stratifies survival.